DNA microarray technology in the clinical environment: The Amplichip CYP450 test for CYP2D6 and CYP2C19 genotyping

CNS Spectrums

Volumn 14, Issue 1, 2009, Pages 19-34

  de Leon, Jose ^a,b,c   Susce, Margaret T ^a   Johnson, Maria ^a   Hardin, Mike ^a   Maw, Lorraine ^a   Shao, Alison ^d   Allen, Antonette C P ^d   Chiafari, Francis A ^d   Hillman, Grantland ^e   Nikoloff, D Michele ^e  

^a Eastern State Hospital   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF GRANADA   (Spain)

^d BRT Laboratories Inc   (United States)

^e Roche Molecular Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; ISOENZYME; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450; UNSPECIFIC MONOOXYGENASE;

AMPLICHIP CYP450 TEST; ARTICLE; CLINICAL LABORATORY; COHORT ANALYSIS; CYP2C19 GENE; CYP2D6 GENE; DNA MICROARRAY; DRUG METABOLISM; ENZYME ACTIVITY; ETHNIC GROUP; FEMALE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; LITERATURE; MENTAL DISEASE; METABOLISM; METHODOLOGY; MULTICENTER STUDY; PHENOTYPE; PREVALENCE; PSYCHIATRY; UNITED STATES;

ARYL HYDROCARBON HYDROXYLASES; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; GENOTYPE; HUMANS; KENTUCKY; MENTAL DISORDERS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PREVALENCE; PSYCHIATRY; REVIEW LITERATURE AS TOPIC;

EID: 62449286261     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900020022     Document Type: Article

References (106)

1. McKusick VA. The anatomy of the humane genome: a neo-vesalian basis for medicine in the 21st century. JAMA 2001;286:2289-2295.
2. Breakthrough of the year. The runners-up. Science. 1997;278:2039-2042.
3. Lertola J. Deciphering the code and what might come from it. Time. 1999;Nov 8:68-69.
4. Collins FS, McKusick VA. Implications of the human genome project for medical science. JAMA. 2001;285:540-544.
5. Fodor SP. Massively parallel genomics. Science 1997;277:393-395.
6. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1988;18:84-112.
7. Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fund Clin Pharmacol 2003;17:27-41.
8. de Leon J. The AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn. 2006;6:277-286.
9. de Leon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 Genotyping Test: integrating a new clinical tool. Mol Diagn Ther. 2006;10:135-151.
10. Human Cytochrome P450 (CYP) Allele Nomenclature Committee Web site. Available at: www.cypalleles.ki.se. Accessed October 28, 2008.
11. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functionary diversity. Pharmacogenomics J 2005;5:6-13.
12. Alan DA, Sharma RP. Cytochrome enzyme genotype and the prediction of therapeutic response to psychotropics. Psychiatr Ann. 2001;31:715-722.
13. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006;47:75-85.
14. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993;90:11825-11829.
15. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-295.
16. Griese EU, Zanger UM, Brudermanns U, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 1998;8:15-26.
17. Solus J, Arietta B, Harris J, et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004;5:895-931.
18. Bjornsson TD, Wagner JA, Donahue SR, et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 2003;43:943-967.
19. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3:229-243.
20. Ingelman-Sundberg M. Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. Drug Metabol Rev. 1999;31:449-459.
21. Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology. 2000;6:174-185.
22. Johnson M, Markham-Abedi C, Susce MT, Murray-Carmichael E, McCollum S, de Leon J. A poor metabolizer for both cytochrome P450 2D6 and 2C19 (CYP2D6 and CYP2C19): a case report on antidepressant treatment. CNS Spectr. 2006;11:757-760.
23. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473.
24. de Leon J. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Current issues in clinical implementation. CNS Spectr. 2006;11(suppl 3):8-12.
25. de Leon J. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 and CYP2C19. J Clin Psychopharmacol 2007;27:241-245.
26. de Leon J, Susce MT, Pan RM, Fairchild M, Koch W, Wedlund PJ. CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66:15-27.
27. DNA Genotek Inc. Products: Oragene•DNA. Available at: http://www.dnagenotek.com/products_oragene.htm. Accessed October 28, 2008.
28. Confidence Interval Analysis (CIA) for Windows software package. In: Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statistics with Confidence 2nd ed. London, UK: BMJ Books; 2000.
29. Cai WM, Nikoloff DM, Pan RM, et al. CYP2D6 genetic variations in healthy adults in psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J. 2006;6:343-350.
30. Gaedigk A, Eklund JD, Pearce RE, et al. Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype. Clin Pharmacol Ther. 2007;81:817-820.
31. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007;17:93-101.
32. Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology. 2005;102:543-549.
33. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007;7:257-265.
34. Black JL 3rd, O'Kane DJ, Mrazek DA. The impact of CYP allelic variation on antidepressant metabolism: a review. Expert Opin Drug Metab Toxicol 2007;3:21-31.
35. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-459.
36. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103-113.
37. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25:5187-5193.
38. Dandara C, Masimirembwa CM, Magimba A, et al. Genetic polymorphism of CYP2D6 and CYP2C19 in eastand southern African populations including psychiatric patients. Eur J Clin Pharmacol. 2001;57:11-17.
39. Daniels J, Williams J, Asherson P, McGuffin P, Owens M. No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT). Am J Med Genet 1995;60:85-87.
40. Dawson E, Powell JF, Nöthen MM, et al. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia. Psychiatr Genet 1994;4:215-218.
41. Rasmussen JO, Christensen M, Svendsen JM, Skausig O, Hansen EL, Nielsen KA. CYP2D6 gene test in psychiatric patients and healthy volunteers. Scand J Clin Lab Invest 2006;66:79-86.
42. Vallada H, Collier D, Dawson E, et al. Debrisoquine 4-hydroxylase (CYP2D) locus and possible susceptibility to schizophrenia [letter]. Lancet. 1992;340:181-182.
43. LLerena A, Dorado P, O'Kirwan F, Jepson R, Licinio J, Wong ML. Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. Pharmacogenomics J. 2004;4:403-406.
44. Luo HR, Gaedigk A, Aloumanis V, Wan YJ. Identification of CYP2D6 impaired functional alleles in Mexican Americans. Eur J Clin Pharmacol. 2005;61:797-802.
45. Chou WH, Yan FX, Robbins-Weilert DK, et al. Comparison of two CYP2D6 genotyping methods and assessments of genotype-phenotype relationships. Clin Chem. 2003;49:542-551.
46. Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry. 2007;40:93-102.
47. Steimer W, Zopf K, von Amelunxen S, et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 2004;50:1623-1633.
48. Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83:234-242.
49. Kirchheiner J. The CYP2D6 phenotype prediction from genotype: which system is best? Clin Pharmacol Ther. 2008;83:225-227.
50. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002;72:76-89.
51. Wennerholm A, Dandara C, Sayi J, et al. The African-specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 2002;71:77-88.
52. Bogni A, Monshouwer M, Moscone A, et al. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. Toxicol In Vitro. 2005;19:621-629.
53. Vermier M, Boom S, Naessens I, et al. Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects. Eur Neuropsychopharmacol. 2005;15:648-649.
54. Dunbar F, Chue P, Fu DJ, et al. Impact of the CYP2D6 metabolizer phenotype on the safety profile of paliperidone ER. Biol Psychiatry. 2007;61(suppl):83S.
55. Nesvåg R, Hendset M, Refsum H, Tanum L. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand 2006;114:21-26.
56. Ruaño G, Makowski G, Windemuth A, et al. High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital: implications for personalized drug safety. Personalized Med. 2006;3:131-137.
57. Brockmoller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002;72:438-452.
58. de Leon J, Diaz FJ, Wedlund P, Josiassen RC, Cooper TB, Simpson GM. Haloperidol half-life after chronic dosing. J Clin Psychopharmacol. 2004;24:656-660.
59. de Leon J, Barnhill J, Rogers T, Boyle J, Chou WH, Wedlund PJ. A pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am J Psychiatry 1998;155:1278-1280.
60. Laine K, Kytölä J, Bertilsson L. Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit. 2004;26:685-687.
61. Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol 2000;10:27-34.
62. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Recommendations from the EGAPP Working Group. Testing for cytochrome P450 polymorphisms in adults with nonpsychotics depression treated with selective serotonin reuptake inhibitors. Genet Med. 2007;9:819-825.
63. Shams ME, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006;31:493-502.
64. McAlpine DE, O'Kane DJ, Black JL, Mrazek DA. Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin Proc. 2007;82:1065-1068.
65. Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44:571-590.
66. Sauer JM, Poinsler GD, Mattiuz EL. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 2003;31:98-107.
67. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002;63:50-55.
68. Allen AJ, Wernicke J, Dunn D, et al. Safety and efficacy of atomoxetine in pediatric CYP2D6 extensive versus poor metabolizers. Presented at: the 57th Annual Meeting of the Society of Biological Psychiatry. May 16-18, 2002; Philadelphia, Penn.
69. Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interaction in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet. 2001;40:753-772.
70. Susce MT, Murray-Carmichael E, de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1356-1358.
71. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Eng J Med. 2004;351:2827-2831.
72. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006;368:704.
73. Lötsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet. 2004;43:983-1013.
74. de Leon J, Dinsmore L, Wedlund PJ. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers [letter]. J Clin Psychopharmacol 2003;23:420-421.
75. de Leon J, Nikoloff DM. Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports. CNS Spectr. 2008;13:133-135.
76. FDA Executive Summary on Tamoxifen and CYP2D6. Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4248B1-01-FDA-Tamoxifen%20Background%20Summary%20Final.pdf. Accessed October 28, 2008.
77. Beverage JN, Sissung TM, Sion AM, et al. CYP2D6 polymorphisms and the mpact on tamoxifen therapy. J Pharm Sci 2007;96:2224-2231.
78. Goetz M, Knox S, Suman V, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen therapy. Breast Cancer Res Treat 2007;101:113-121.
79. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast. J Clin Oncol 2007;25:3837-3845.
80. Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 2008;99:885-999.
81. Xu Y, Sun Y, Yao L, et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 2008;19:1423-1429.
82. Bonanni B, Macis D, Maisonneuve P, et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian tamoxifen trial. J Clin Oncol 2006;24:3708-3709.
83. Wang JH, Liu ZQ, Wang W, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001;70:42-47.
84. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 2005;33:262-270.
85. Mrazek DA. Are the 5HT transporter and/or the P450 isonezyme genes associated with response/remission to citalopram. Biol Psychiatry. 2006;59(suppl):105S.
86. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 2008;83:322-327.
87. Desta Z, Zhao X, Shin J, Flockhart D. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913-958.
88. Inomata S, Nagashima A, Itagaki F, et al. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther 2005;78:647-655.
89. de Leon J. The potential of genotyping [letter]. Science 2008;321:769.
90. de Leon J, Arranz MJ, Ruaño G. Products for pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med. 2008;28:599-617.
91. de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 2009;34:159-172.
92. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of the last decade of research. Mol Psychiatry. 2007;12:707-747.
93. de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005;46:262-273.
94. Duggan M. Do new prescription drugs pay for themselves? The case of secondgeneration antipsychotics. J Health Econ. 2005;24:1-31.
95. Rosenheck RA, Leslie DL, Doshi JA. Second-generation antipsychotics: costeffectiveness, policy options, and political decision making. Psychiatr Serv 2008;59:515-520.
96. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry. 2007;164:415-427.
97. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of firstand secondgeneration antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry. 2008 Sept 15. [Epub ahead of print].
98. de Leon J, Diaz FJ. Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. Schizophr Res. 2007;96:185-197.
99. de Leon J, Correa JC, Ruaño G, Windemuth A, Arranz MJ, Diaz FJ. Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr Res 2008;98:40-46.
100. de Leon J. Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, and co-morbid substance use [editorial]. J Clin Psychopharmacol 2008;28:125-131.
101. Ozdemir V, Aklillu E, Mee S, et al. Pharmacogenetics for off-patent antipsychotcs: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother 2006;7:119-133.
102. de Leon J, Susce MT, Pan RM, Koch W, Wedlund PJ. Polymorphic variations n GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005;25:448-456.
103. Ruaño G, Goethe JW, Caley C, et al. Physiogenomic comparison of weight profiles of olanzapineand risperidone-treated patients. Mol Psychiatry 2007;12:474-482.
104. de Leon J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res. 2008 Oct 17. [Epub ahead of print].
105. de Leon J, Sandson NB, Cozza KL. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II. Psychosomatics 2008;49:347-361.
106. Wolf CR, Smith G, Smith RL. Science, medicine, and the future: pharmacogenetcs. BMJ 2000;320:987-990.